tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Prolonged Development Timelines and Limited Near-Term Catalysts Lead to Sell Rating for Y-Mabs Therapeutics
PremiumRatingsProlonged Development Timelines and Limited Near-Term Catalysts Lead to Sell Rating for Y-Mabs Therapeutics
2M ago
Cautious Outlook on Y-Mabs Therapeutics Due to Delayed Milestones and Early-Stage Pipeline
Premium
Ratings
Cautious Outlook on Y-Mabs Therapeutics Due to Delayed Milestones and Early-Stage Pipeline
2M ago
Y-Mabs Therapeutics Updates on Radiopharmaceutical Progress
Premium
Company Announcements
Y-Mabs Therapeutics Updates on Radiopharmaceutical Progress
2M ago
Y-mAbs Therapeutics Reports Q1 2025 Financial Results
PremiumCompany AnnouncementsY-mAbs Therapeutics Reports Q1 2025 Financial Results
2M ago
Cautious Outlook on Y-Mabs Therapeutics Amidst Competitive and Enrollment Challenges
Premium
Ratings
Cautious Outlook on Y-Mabs Therapeutics Amidst Competitive and Enrollment Challenges
2M ago
UnitedHealth suspends outlook, Under Armour reports Q4 beat; Morning Buzz
Premium
The Fly
UnitedHealth suspends outlook, Under Armour reports Q4 beat; Morning Buzz
2M ago
Y-mAbs Therapeutics announces naxitamab-gqgk recommended by NCCN
PremiumThe FlyY-mAbs Therapeutics announces naxitamab-gqgk recommended by NCCN
3M ago
Y-mAbs Therapeutics announces presentation of PK data of CD38-SADA
Premium
The Fly
Y-mAbs Therapeutics announces presentation of PK data of CD38-SADA
3M ago
Y-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA PRIT platform
Premium
The Fly
Y-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA PRIT platform
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100